Journal: Cell Reports Medicine

Article Title: Dual PD-1/IL-2Rα targeting restores CD8 + T cell fitness via STAT5/CD47 axis in SMARCA4-deficient NSCLC

doi: 10.1016/j.xcrm.2026.102633

Figure Lengend Snippet: PD-1/IL-2 bsAb protects CD8 + T cells from macrophage phagocytosis via STAT5-mediated upregulation of CD47 (A) Schematic of the Cleavage Under Targets and Tagmentation (CUT&Tag) assays workflow. (B) Distribution of STAT5 binding signals relative to transcription start sites (TSS) in CD8 + T cells treated with or without the PD-1/IL-2 bsAb. (C) Genomic annotation of differentially enriched STAT5 binding peaks in the bsAb-treated group. (D) KEGG pathway enrichment analysis of genes associated with STAT5 binding peaks. (E and F) Strategy and Venn diagram for identifying potential STAT5 downstream genes. (G) ChIP-qPCR analysis of STAT5 binding to the promoter regions of selected candidate genes ( n = 3). (H) Genome browser tracks showing STAT5 binding signals at the CD47 locus in control and PD-1/IL-2 bsAb-treated CD8 + T cells. (I) Schematic of the macrophage phagocytosis assay. (J) Representative confocal microscopy images showing macrophages (red) engulfing CD8 + T cells (green). Scale bars, 20 μm. (K) Flow cytometry quantification of the percentage of macrophages that had phagocytosed CD8 + T cells under the indicated conditions ( n = 3). Data are represented as mean ± SD (error bars) from biological replicates. Statistical analyses, n.s., no significance. Statistical significance was determined by unpaired Student’s t test or one-way ANOVA where appropriate.

Article Snippet: CD47 (E2V9V) Rabbit mAb , Cell Signaling Technology , Cat#36096.

Techniques: Binding Assay, ChIP-qPCR, Control, Phagocytosis Assay, Confocal Microscopy, Flow Cytometry

Journal: Cell Reports Medicine

Article Title: Dual PD-1/IL-2Rα targeting restores CD8 + T cell fitness via STAT5/CD47 axis in SMARCA4-deficient NSCLC

doi: 10.1016/j.xcrm.2026.102633

Figure Lengend Snippet: CD47 protects CD8 + T cells from macrophage clearance to boost antitumor immunity in SMARCA4-deficient NSCLC (A) Schematic of the adoptive T cell therapy experiment ( n = 8/group). (B) Representative in vivo bioluminescence images of mice from the indicated treatment groups at different time points. (C) Tumor growth curves, as measured by bioluminescence, for mice in each treatment group. (D) Individual tumor growth curves for mice in each treatment group. (E) Kaplan-Meier survival curves of mice from the four treatment groups. (F) Quantification by flow cytometry of donor-derived CD45.2 + CD8 + T cells among total tumor-infiltrating lymphocytes. (G) Representative flow cytometry plots for donor-derived CD45.2 + CD8 + T cells expressing the exhaustion markers PD-1, TIGIT, and TIM-3. (H) Quantification of the percentage of CD45.2 + CD8 + T cells expressing PD-1, TIGIT, and TIM-3. (I) The production of TNF-α by donor-derived CD45.2 + CD8 + T cells. (J) The production of IFN-γ by donor-derived CD45.2 + CD8 + T cells. (K) Representative immunofluorescence images of tumor sections. White: CD8, green: CD47, red: F4/80. Scale bars, 70 μm. (L) Schematic model depicting the proposed mechanism of action. Data are represented as mean ± SD (error bars) from biological replicates. Statistical analyses, n.s., no significance. Statistical significance was determined by one-way ANOVA.

Article Snippet: CD47 (E2V9V) Rabbit mAb , Cell Signaling Technology , Cat#36096.

Techniques: In Vivo, Flow Cytometry, Derivative Assay, Expressing, Immunofluorescence

Journal: European Journal of Microbiology & Immunology

Article Title: CD47 monoclonal antibodies differ in their capacity to induce immune response

doi: 10.1556/1886.2025.00065

Figure Lengend Snippet: Anti-CD47 clone MIAP301 treatment induces stronger myeloid immune activation. C57BL/6 mice were treated with anti-CD47 clone MIAP410, anti-CD47 clone MIAP301, or isotype control i.p. (100 µg/mouse, daily) for two days. Mice were infected with 2 × 10 6 PFU/200 µL LCMV intravenously. (A) RT-PCR analysis for IFNα4, IFNβ1, and Mx1 was performed on RNA extracted from the spleen. (B) Total circulating CD11b + , CD11b + Ly6C, and CD11 + circulating cells in blood. (C) Percentage of CD11b + Cy3 + cells in mice treated with anti-CD47 MIAP410 or MIAP301 or isotype infected with 2 × 10 6 LCMV-Cy3 i.v. The data shown was confirmed in two independent experiments ( n = 6) and is shown as mean ± SEM. The statistical comparison of infected vs. control mice was performed using Student's t -test (* P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001)

Article Snippet: Anti-CD47 monoclonal antibodies clone MIAP410 (Cat no: BE0283) and MIAP301 (Cat no: BE0270) used in this study were purchased from Bio X Cell.

Techniques: Activation Assay, Control, Infection, Reverse Transcription Polymerase Chain Reaction, Comparison

Journal: European Journal of Microbiology & Immunology

Article Title: CD47 monoclonal antibodies differ in their capacity to induce immune response

doi: 10.1556/1886.2025.00065

Figure Lengend Snippet: Treatment of MIAP301 and MIAP410 induces an inconsequential difference in NK cell response. C57BL/6 mice were treated with anti-CD47 MIAP410 or MIAP301, or isotype control i.p. (100 µg/mouse, daily) for 2 days and were infected with LCMV for 24 h. (A) Gating strategies of splenic NK cells and (B) percentage of NK1.1 + cells. Intracellular cytokine staining of IFN-γ, perforin, and granzyme B on splenocytes. Percentage of (C) perforin + and granzyme B + NK cells, (D) IFN-γ + NK cells, and (E) CD107a + NK cells. The data shown was confirmed in two independent experiments ( n = 6) and is shown as mean ± SEM. The statistical comparison of infected vs. control mice was performed using Student's t -test (* P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001)

Article Snippet: Anti-CD47 monoclonal antibodies clone MIAP410 (Cat no: BE0283) and MIAP301 (Cat no: BE0270) used in this study were purchased from Bio X Cell.

Techniques: Control, Infection, Staining, Comparison

Journal: European Journal of Microbiology & Immunology

Article Title: CD47 monoclonal antibodies differ in their capacity to induce immune response

doi: 10.1556/1886.2025.00065

Figure Lengend Snippet: MIAP301 and MIAP410 treatment led to a subtle difference in T cell activation and function. C57BL/6 mice were treated with anti-CD47 MIAP410 or MIAP301 or isotype control i.p. (100 µg/mouse, daily) for −2, 0, 1, and 4 days and infected with LCMV for 8 days. (A) Gating strategies of CD8 + T cells from blood. (B) Total circulating CD8 + T cells and LCMV-gp33-specific CD8 + T cells in the blood. (C) Total CD4 + T cells in the blood. Percentage of (D) IFN-γ + CD8 + T cells and (E) IFN-γ + CD4 + T cells from splenocytes. The data shown was confirmed in two independent experiments ( n = 6) and is shown as mean ± SEM. The statistical comparison of infected vs. control mice was performed using Student's t -test (* P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001)

Article Snippet: Anti-CD47 monoclonal antibodies clone MIAP410 (Cat no: BE0283) and MIAP301 (Cat no: BE0270) used in this study were purchased from Bio X Cell.

Techniques: Activation Assay, Control, Infection, Comparison